The Effects of Moclobemide on Psychomotor Performance and Cognitive Function in the Elderly

Hindmarch, Ian; Kerr, John; Fairweather, D. B.

doi:10.1159/000107038

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to amitriptyline, both moclobemide doses were free of significant behavioral and detrimental effects on shortterm memory. Furthermore, in elderly volunteers moclobemide, at single doses, did not differ from placebo in tests of psychometric performance and cognitive function (80). Another controlled study testing up to 600 mg moclobemide over 1 week against placebo also found no impairment of attention, performance and cognition in healthy young and elderly volunteers (73).…”

Section: Cognition and Driving Performancementioning

confidence: 99%

See 1 more Smart Citation

Moclobemide: Evolution, Pharmacodynamic, and Pharmacokinetic Properties

Bonnet¹

2002

CNS Drug Reviews

View full text Add to dashboard Cite

The benzamide moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA). It has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively in anxiety disorders. While clinical aspects will be presented in a subsequent review, this article focuses primarily on moclobemide's evolution, pharmacodynamic and pharmacokinetic properties. In particular, the effects on neurotransmission and intracellular signal transduction, the neuroendocrine system, the tyramine pressure response and animal models of depression are surveyed. In addition, other CNS effects are reviewed with special respect to experimental serotonergic syndrome, anxiolytic and antinociceptive activity, sleep, cognition and driving performance, neuroprotection and seizures.

show abstract

Section: Cognition and Driving Performancementioning

confidence: 99%

“…With particular reference to driving performance, moclobemide was found to be devoid of detrimental effects on psychomotor performance as assessed by critical fusion flicker frequency, choice reaction time and tracking accuracy (40,73,79,80,137).…”

Section: Cognition and Driving Performancementioning

confidence: 99%

Moclobemide: Evolution, Pharmacodynamic, and Pharmacokinetic Properties

Bonnet¹

2002

CNS Drug Reviews

View full text Add to dashboard Cite

show abstract

“…Reported prevalence rates of depression in Alzheimer's disease and vascular dementia range between 17 and 40% (7). As moclobemide was found to be devoid of anticholinergic and sedative effects in several performance tests (64,110,111,197) and may even improve disturbed cognitive function (2,8,79,183,255), it may be well suited for the treatment of elderly depressed patients with major cognitive deficits. This possibility was tested and two studies (183,201) support this assumption.…”

Section: Organic Depression Depression and Dementiamentioning

confidence: 99%

Moclobemide: Therapeutic Use and Clinical Studies

Bonnet¹

2003

CNS Drug Reviews

205

100

View full text Add to dashboard Cite

Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied in anxiety disorders. Nearly all meta-analyses and most comparative studies indicated that in the acute management of depression this drug is more efficacious than placebo and as efficacious as tricyclic (or some heterocyclic) antidepressants or selective serotonin reuptake inhibitors (SSRIs). There is a growing evidence that moclobemide is not inferior to other antidepressants in the treatment of subtypes of depression, such as dysthymia, endogenous (unipolar and bipolar), reactive, atypical, agitated, and retarded depression as with other antidepressants limited evidence suggests that moclobemide has consistent long-term efficacy. However, more controlled studies addressing this issue are needed. For patients with bipolar depression the risk of developing mania seems to be not higher with moclobemide than with other antidepressants. The effective therapeutic dose range for moclobemide in most acute phase trials was 300 to 600 mg, divided in 2 to 3 doses. While one controlled trial and one long-term open-label study found moclobemide to be efficacious in social phobia, three controlled trials subsequently revealed either no effect or less robust effects with the tendency of higher doses (600 -900 mg /d) to be more efficacious. Two comparative trials demonstrated moclobemide to be as efficacious as fluoxetine or clomipramine in patients suffering from panic disorder. Placebocontrolled trials in this indication are, however, still lacking.A relationship between the plasma concentration of moclobemide and its therapeutic efficacy is not apparent but a positive correlation with adverse events has been found. Dizziness, nausea and insomnia occurred more frequently on moclobemide than on placebo. Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri-or heterocyclic antidepressants. Gastrointestinal side effects and, espe-97

show abstract

Cognition and anxiety: the cognitive effects of anti‐anxiety medication

Hindmarch

1998

Acta Psychiatr Scand

View full text Add to dashboard Cite

There does not appear to be a single hypothesis or theory which can adequately explain the aetiology of anxiety, although there is no shortage of contenders. Neurochemical, existential, sociogenic, familial, pathological, psychodynamic and behavioural explanations have all been offered as putative reasons for the psychological disorder, which in its various representations (panic disorder, obsessive‐compulsive disorder, phobias, post‐traumatic stress disorder, generalized anxiety disorders, etc.) can affect up to 20% of the population on a lifetime basis (1). Notwithstanding the variety of theories and the diversity of presentation of anxiety disorders, it would appear that cognitive dysfunction of one sort or another is a characteristic feature of anxiety in all its manifestations. Indeed, it is possible to argue that a cognitive impairment is the primary presenting feature of pathological anxiety, with the characteristic syndrome of somatic symptoms as secondary or necessary consequences of such cognitive disorder.

show abstract

The Effects of Moclobemide on Psychomotor Performance and Cognitive Function in the Elderly

Cited by 3 publications

References 22 publications

Moclobemide: Evolution, Pharmacodynamic, and Pharmacokinetic Properties

Moclobemide: Evolution, Pharmacodynamic, and Pharmacokinetic Properties

Moclobemide: Therapeutic Use and Clinical Studies

Cognition and anxiety: the cognitive effects of anti‐anxiety medication

Contact Info

Product

Resources

About